Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19726655 | 0.97 | SMN1; SMN2 (0.44) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL19726654 | 0.92 | HPGD (0.44) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL19732580 | 0.91 | HPGD (0.43) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17885894 | 0.89 | SMN1; SMN2 (0.48) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL20008742 | 0.83 | SMN1; SMN2 (0.48) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL14074488 | 0.82 | NAMPT (0.38) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL25672072 | 0.81 | SMN1; SMN2 (0.41) | HPGDHTTSMN1; SMN2POLBHSD17B10 | |
| SCHEMBL20365824 | 0.80 | SMN1; SMN2 (0.46) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL19732579 | 0.80 | SMN1; SMN2 (0.46) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17175680 | 0.79 | HPGD (0.39) | HPGDHTTSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | HPGD 2327/4885HTT 2150/4885SMN1; SMN2 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.